OGC
BBH icon

Oak Grove Capital’s VanEck Biotech ETF BBH Stock Holding History

Oak Grove Capital’s Portfolio BBH Stock Details BBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-500
Closed -$68K – 74
2018
Q3 		$68K Hold
500
– – 0.06% 70
2018
Q2 		$60K Hold
500
– – 0.06% 62
2018
Q1 		$60K Buy
+500
New +$62.7K 0.07% 65

Other funds holding BBH

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
MCM
Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
SFS
Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
MJRIC
Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Oak Grove Capital's BBH Position: Q4 2018 in Review

Oak Grove Capital sold out of VanEck Biotech ETF (BBH) in Q4 2018, closing a stake of 500 shares — an estimated $68K sold.

Oak Grove Capital first reported a position in BBH in Q1 2018 and held it in 3 quarters. The position peaked at $68K in Q3 2018. 84 funds tracked by Wall St. Rank hold BBH as of Q4 2018.

  • Oak Grove Capital reported no remaining VanEck Biotech ETF position as of Q4 2018 after selling out during the quarter.
  • Oak Grove Capital sold 500 VanEck Biotech ETF shares in Q4 2018, an estimated $68K.
  • Oak Grove Capital first reported a position in VanEck Biotech ETF in Q1 2018 and held it in 3 quarters.
  • Oak Grove Capital's VanEck Biotech ETF position peaked at $68K in Q3 2018.
  • 84 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q4 2018.

Based on Oak Grove Capital's 13F filing for Q4 2018, filed 15 Feb 2019.